714 results about "Biological effect" patented technology

An apparatus and method for treating subcutaneous tissues using acoustic waves in the range of low acoustic pressure ultrasound waves is disclosed. The method includes injections of enhancing agents, wherein disruption of subcutaneous tissues and subcutaneous cavitational bioeffects are produced by ultrasound waves having a power that will not produce tissue cavitation in the absence of the enhancing agents. The apparatus and method of use is useful for treatment of subcutaneous abnormalities including cellulite, lipomas, and tumors.

A device for generating at least blue light comprises a control circuit (4) which receives a control signal (CS) defining a variation of a spectrum of the blue light to control a photo-biological effect of a vertebrate. Therefore, first blue light (BL1) is generated with a first predominant wavelength (PW1) having a first photo-biological effect, or second blue light (BL2) is generated with both a second predominant wavelength (PW2), being shorter than the first predominant wavelength, and a third predominant wavelength (PW3), being longer than the first predominant wavelength; the second blue light (BL2) has a second photo-biological effect different from the first photo-biological effect, while the first blue light (BL1) and the second blue light (BL2) have substantially identical colors and intensities.

The invention provides a method for preventing and treating the harmful biological effects of biochemicals secreted from activated mast cells in the organism of warm blooded animals and more especially human beings, said effects being associated with allergy (including but not limited to allergic conjunctivitis, allergic rhinitis, allergic otitis, asthma, allergic uticaria, food allergy and atopic dermatitis), hyperproliferative diseases such as leukemia and systemic mastocytosis, interstitial cystitis, inflammatory bowel disease, irritable bowel syndrome, osteoporosis and scleroderma. The method consists in administering to said animals and especially to human beings an effective amount of a proteoglycan such as chondroitin sulfate with mast cell secretion inhibitory activity, alone or in combination with one or more synergistic adjuvants such those belonging to the class of flavonoids or compounds with histamine-1 receptor antagonist activity.

Provided herein are methods of culturing cells in vitro in order to exploit the biochemical production ability of the cells to make metabolites that are evaluated and harvested for their biological effects. Also provided are systems for evaluating extracts from such cultured cells to characterize their biological activity(s), particularly with regard to impact on health, wellbeing, longevity, DNA maintenance, mitochondrial health and / or biogenesis, and so forth. Biologically active extracts, components thereof, and compositions (such as cosmetic or pharmaceutical preparations) made comprising such, are also provided.

A novel x-ray treatment system utilizes one or more large area flat panel sources of x-ray radiation directed into a target zone. A target substance within the target zone is irradiated with x-ray radiation from the one or more flat panel sources, reducing the biological effects of a contaminant presence therein. The flat panel source comprises an electron source, an electron accelerator, and an electron target medium. The electron source may emit electrons either via field emission or thermionic emission. The x-ray source may operate in transmissive, reflective, or combined transmissive / reflective mode. The use of large area flat panel x-ray sources in the inventive systems allows for decreased installation and operational costs as well as increased efficiency.

The invention relates nucleic acids and their encoded polypeptides, whose expression is modulated in cancer or tumor cells. The invention further relates to methods useful for treating or modulating cancer or tumors in mammals in need of such biological effect. This includes the diagnosis and treatment of oncological disorders. Additionally, the present invention further relates to the use of antibodies against the polypeptides of the present invention as diagnostic probes or as therapeutic agents as well as the use of polynucleotide sequences encoding the polypeptides of the present invention as diagnostic probes or therapeutic agents for the treatment of a broad range of pathological states.

The invention relates to a processing method of sea cucumber glycopeptides chelated calcium. The method comprises the following steps: A. material treatment: cleaning sea cucumber mouthparts, cooking, soaking, beating, and homogenizing; B. biological enzymatic hydrolysis: choosing a variety of protease for composite segmented enzymatic hydrolysis; C. centrifugal separation: conducting continuous centrifugal separation on an enzymolysis liquid to obtain the sea cucumber glycopeptides solution and sea cucumber calcium precipitate; D. filtration, concentration and grading: subjecting the enzyme liquid to ultrafiltration fractionation concentration, and desalinating small peptide filtered solution by nanofiltration; E. preparation of sea cucumber calcium by organic acidolysis; G. chelating reaction: promoting the chelating of sea cucumber calcium and glycopeptides of sea cucumber by microwave assistance; and H. after the reaction, carrying out centrifuging separation, and drying the precipitate and supernatant respectively. The present invention comprehensively utilizes the sea cucumber processing waste to prepare sea cucumber autologous calcium and autologous glycopeptides for chelation. The method on the one hand is beneficial to playing their biological effects, and on the other hand can also obtain five products with different specific biological functions.

A lighting system for creating a biological effect induced by light. The biological effect is a different effect than vision. The lighting system comprises a light source (1) to generate light with a varying spectrum, and a driver (2) to drive the light source (1) to successively in time: (i) generate a first spectrum (S1) during a first period in time (T1), (ii) change the first spectrum (S1) into a second spectrum (S2) during a second period in time (T2), wherein the second spectrum (S2) has the biological effect, and (iii) maintain the second spectrum (S2) during a third period in time (T3). The duration of the second period in time (T2) is selected in a range from 5 seconds to 30 minutes. The first spectrum (S1) may not have the biological effect or may have the biological effect to a smaller extent than the second spectrum (S2).

Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agent are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided.

The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain barrier functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides herein. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain barrier properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain / retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.

The novel germ-line transformation systems disclosed in this patent application allow the physical deletion of transposon DNA following the transformation process, and the targeting of transgene integrations into predefined target sites. In this way, transposase-mediated mobilization of genes-of-interest is excluded mechanistically and random genomic integrations eliminated. In contrast to conventional germ-line transformation technology, our systems provide enhanced stability to the transgene insertion. Furthermore, DNA sequences required for the transgene modification (e.g. transformation marker genes, transposase or recombinase target sites), are largely removed from the genome after the final transgene insertion, thereby eliminating the possibility for instability generated by these processes. The RMCE technology, which is disclosed in this patent application for invertebrate organisms (exemplified in Drosophila melanogaster) represents an extremely versatile tool with application potential far beyond the goal of transgene immobilization. RMCE makes possible the targeted integration of DNA cassettes into a specific genomic loci that are pre-defined by the integration of the RMCE acceptor plasmid. The loci can be characterized prior to a targeting experiment allowing optimal integration sites to be pre-selected for specific applications, and allowing selection of host strains with optimal fitness. In addition, multiple cassette exchange reactions can be performed in a repetitive way where an acceptor cassette can be repetitively exchanged by multiple donor cassettes. In this way several different transgenes can be placed precisely at the same genomic locus, allowing, for the first time, the ability to eliminate genomic positional effects and to comparatively study the biological effects of different transgenes.

An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested / shown that C20:5n-3 (and C22:6 n-3) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.

Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

The invention relates to an intramedullary nail system including an elongated nail member comprising a cavity and electrically conductive at least in part, a coil assembly, a first electrode connected to a first pole of the coil assembly and a second electrode connected to a second pole of the coil assembly. To improve such an intramedullary nail system particularly as regards its convenience in handling and flexible application during the operation, its stability, its biological effect, its therapeutical effectiveness and its economy it is provided for that the coil assembly is provided in an end cap assembly proximally releasably connected to the nail member with an outer contact surface being electrically conductive at least in part, that the contact surface is electrically insulated from the nail member, that at least one section of the contact surface forms the first electrode and that at least one section of the nail member forms the second electrode.

The invention relates to hydrogel as well as a preparation method and a purpose of the hydrogel. The hydrogel is prepared through electron beam or Gamma-ray radiation on natural polymers or derivates of the natural polymers after the medicine active ingredient loading in oxygen-free environment. The hydrogel has good biocompatibility and use safety, the biological effects of the natural polymers or the derivates of the natural polymers on the wound healing and the skin repair protection can be permanently and fully exerted in local parts in the hydrogel mode, good medicine slow release functions of the hydrogel are also fully utilized, the required medicine active ingredients are specifically added, good efficiencies and wide purposes are given to the hydrogel, and the hydrogel can be used in the fields of skin, mucosa and cornea wound dressings, filling materials, tissue engineering materials, cell culture media and the like, and can also be used in the field of daily use articles such as skin care products and cosmetics.

A magnetic field generator includes a power source and a coil connected to the power source to generate a time-varying magnetic field. Energy is applied to the coil so that the coil generates a time-varying magnetic field gradient with a magnitude of at least 1 milliTesla per meter and a rise-time of less than 10 microseconds. One or more of a capacitor, a multi-stage high-voltage switch, and / or a pulse-forming network may assist with the generation of the magnetic field gradient.

A system for the variable rate application of pesticides is provides, comprising a) a vehicle capable of traversing an agricultural production area; b) at least one sensor for attachment to said vehicle for direct sensing plant and / or condition data on said agricultural production area, said sensor being capable of transmitting said directly sensed data to computing means; c) computing means for processing the data output of said sensor; d) at least one tank mounted on or attached to said vehicle carrying pesticidal formulations; e) pesticide delivery means mounted on or attached to said vehicle capable of receiving delivery instructions from said computing means and of delivering pesticides from said tank in compliance with said instructions; characterized in that f) said computing means is capable of reading and processing data from a computer-readable medium having stored thereon a plurality of data, said plurality of data including data relating to the functional relationship between the amounts of individual pesticides and the biological effects achievable with said amounts on the plants or their environment, optionally under consideration of the soil conditions and climatic conditions.

Larmor Precession makes specific predictions about bound ion dynamics, based upon specific combinations of AC and DC magnetic fields. Especially significant is the fact that the external magnetic field environment determines the overall qualities of resonances or particular changes in bio-effects. Given a target with a particular gyromagnetic ratio, Larmor Precession makes predictions that are determined solely by a magnetic field environment itself. An embodiment according to the present invention comprises specific combinations of AC and DC magnetic fields configured to produce specific bio-effects. Preferably an embodiment according to the present invention comprises using Larmor Precession to develop Electromagnetic Field environments targeted towards enhancing or diminishing specific biological processes, including tumor growth, bone and tissue repair, and biological processes and using Larmor Precession to generate magnetic field conditions that take advantage of specific behaviors, including resonances conditions.

Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agent are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided.

A lighting system for creating a biological effect induced by light. The biological effect is a different effect than vision. The lighting system comprises a light source (1) to generate light with a varying spectrum, and a driver (2) to drive the light source (1) to successively in time: (i) generate a first spectrum (S1) during a first period in time (T1), (ii) change the first spectrum (S1) into a second spectrum (S2) during a second period in time (T2), wherein the second spectrum (S2) has the biological effect, and (iii) maintain the second spectrum (S2) during a third period in time (T3). The duration of the second period in time (T2) is selected in a range from 5 seconds to 30 minutes. The first spectrum (S1) may not have the biological effect or may have the biological effect to a smaller extent than the second spectrum (S2).

The invention discloses a preparation method of double-targeting cationic ultrasound microbubbles carrying cell-penetrating peptide iRGD and belongs to the field of fundamental research. The preparation method uses materials, including DSPC, DSPE-PEG2000-maleimide, DSPE-PEG2000-Biotin, iRGD peptide, CCR2 antibody, stearic acid, branched-chain polyetherimide-600, N, N'-carbonyldiimidazole, and avidin; by bonding integrin Alpha v Beta3 targeting cell-penetrating peptide iRGD and the CCR2 antibody to surfaces of the microbubbles, double-targeting cationic ultrasonic contrast agent is constructed and has the double functions of carrying plasmid DNA and targeting tumor cells; combining ultrasound-mediated biological effect and iRGD cell-penetrating action, the agent is capable of promoting entry of genes into the tumor cells and improving gene transfection efficiency and is expected to be developed and applied to visual ultrasound-controlled-release genetic treatment of tumors.

A method and apparatus to measure and analyze electromagnetic emissions from implanted electronics to accomplish at least one of: detect and identify an active implant comprising electronics implanted in a biological host, diagnose the health of individual electronics as well as their health as an ensemble, and predict probable degradation of individual electronics, degradation of the electronic ensemble, and of the active implant in an automated fashion. The methods comprise filtering techniques to extract the information about the active implant's electronics by filtering out relevant biological effects induced by the active implant's biological situation. Said detection, identification, diagnosis, and prognosis are based on the measurement of intentional and unintentional electromagnetic emissions that emanate from the implant electronics of the active implant in a given biological situation.

The present invention provides a bioreacto 1r for incubation of cell cultures, tissue biopsies, cell clusters, tissue-like structures, ‘prototissues’ or similar samples. The bioreactor is generally adapted for rotation for use in microgravity conditions and equipped with an incubation cavity having a small internal fluid volume, generally less than 1 ml. To avoid problems associated with small volume incubation, the bioreactor may include a humidity chamber or other means of avoiding dehydration as well as substantially fluid-tight closures for access ports that avoid introduction of air bubbles to the incubation cavity. The small-volume bioreactor permits long term maintenance of tissue differentiation states in cultures. Also provided are methods of incubating cells or tissues using the bioreactor including methods of creating molecular profiles of biological effects of chemical compositions on differentiated cell or tissue samples maintained in long term culture.

The present invention relates to linear expression elements (LEEs) and circular expression elements (CEEs), which are useful in a variety of molecular biology protocols. Specifically, the invention relates to the use of LEEs and CEEs to screen for gene function, biological effects of gene function, antigens, and promoter function. The invention also provides methods of producing proteins, antibodies, antigens, and vaccines. Also, the invention relates to methods of making LEEs and CEEs, and LEEs and CEEs produced by such methods.

The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.

The invention discloses a device and a method for treating low-temperature high-ammonia nitrogen wastewater by use of a constant magnetic field. The device mainly comprises a shortcut nitrification SBR reactor, magnetic field intensifying devices symmetrically arranged on the two sides of the reactor, an online shortcut nitrification monitoring system and a feedback control system. According to the device and the method, the magnetic biological effect is thoroughly utilized, and the active sites of proteins in the ammonia monooxygenase and the hydroxylamine oxidase of ammonia-oxidizing bacteria are affected by use of the magnetic field, and therefore, the activity of the enzymes is improved, the ammoxidation reaction rate is increased and the enrichment of the ammonia-oxidizing bacteria is promoted, and especially, the influence of the temperature to the activity of the enzyme can be compensated under a low temperature condition; besides, the speed of movement of charged particles is increased by use of the action of the magnetic field force, and furthermore, the mass transfer efficiency is improved, the defects of unstable operation of the reactor, low ammonia nitrogen degradation rate and the like in existing low-temperature wastewater treatment are made up, and meanwhile, efficient nitrosation is realized in the reactor under the low-temperature condition by controlling dissolved oxygen, pH, hydraulic retention time and sludge age; and as a result, the sewage retention time is shortened and the cost and the energy consumption are reduced.

Provided are methods of using gelsolin and active fragments thereof to neutralize, treat or prevent the pathogenic effects of lipopolysaccharide (LPS) endotoxins released from gram-negative bacteria, including massive activation of inflammatory response in a patient and the resulting lethal septic shock. The provided gelsolin binds LPS from various bacteria with high affinity, decreasing circulating LPS and neutralizes its deleterious biological effects. Consequently, the provided gelsolin replacement therapy offers a method for the prevention of LPS-induced mortality in the patient.

A tracing or marking isotope micro-bubble reagent with targeting substance, the combination or mixture of ultrasonic micro-bubble imaging reagent with tracing or marking isotope. The tracing or marking isotope includes generally medical used isotopes. The micro-bubble reagent includes fluoro-carbon type, medical salt water type, semi lactose bubble liquid type, envelope bubble liquid type and carbon dioxide generating type. Large molecule substance is selected as the carrier of ultrasonic reagent to wrap, stick, stabilize and carry the bubbles. The tracing or marking isotope micro-bubble reagent with targeting substance is applied to position the tumor area in the treatment of tumor by using low frequency, low energy ultrasonic to induce the cavitation effect of micro-bubbles to form thrombus embolus in blood vessels, Meanwhile, radial β isotope is applied to radiate the tumor cells by using the ionizing radiation biological effect thereof.